Barclays PLC Aurinia Pharmaceuticals Inc. Put Options Transaction History

Barclays PLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$4.93 - $9.31 $46,835 - $88,445	9,500 Added 28.79%	42,500 $213,000
Q4 2023 Feb 15, 2024	BUY	$7.13 - $9.49 $235,290 - $313,170	33,000 New	33,000 $297,000
Q4 2021 Feb 14, 2022	BUY	$17.78 - $33.08 $378,714 - $704,604	21,300 Added 215.15%	31,200 $714,000
Q4 2019 Feb 10, 2020	SELL	$3.88 - $21.42 $514,488 - $2.84 Million	-132,600 Reduced 93.05%	9,900 $201,000
Q3 2019 Nov 14, 2019	BUY	$5.34 - $6.59 $493,950 - $609,575	92,500 Added 185.0%	142,500 $761,000
Q3 2018 Nov 14, 2018	BUY	$5.27 - $6.64 $263,500 - $332,000	50,000 New	50,000 $332,000

191

56.2M

499K

637K

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.03B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.